Fulcrum Therapeutics, Inc. Share Price

Fulcrum Therapeutics, Inc. Share Price

NASDAQ: FULC | Micro Cap
$3.76
+$0.03 (0.80%) Last updated on 18 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Fulcrum Therapeutics, Inc. Stock Performance

Open
$3.73
Prev. Close
$3.73
Circuit Range
N/A
Day Range
$3.71 - $3.75
Year Range
$2.92 - $15.46
Volume
66,782
Average Traded
$3.73

Fulcrum Therapeutics, Inc. Share Price Today

As of 18 November 2026, Fulcrum Therapeutics, Inc.'s share price is $3.76. The stock opened at $3.73, compared to its previous close of $3.73. During today's trading session, Fulcrum Therapeutics, Inc.'s share price traded between $3.71 and $3.75, with an average price of $3.73. Over the past 52 weeks, the stock has recorded a high of $15.46 and a low of $2.92. In terms of performance, Fulcrum Therapeutics, Inc.'s share price has declined by 45.74% over the last six months and is down 65.69% on a year-on-year basis.

Fulcrum Therapeutics, Inc. Share Price Chart

Line chart of the Fulcrum Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 3.71 to 3.76, ending at 3.76.
$3.71$3.75
L
Show Current Price
H

Fulcrum Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$238214.80
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.00
Revenue (TTM)
$0.00
Return On Equity (TTM)
-25.28%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
46.19%

Fulcrum Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$20.33-$18.89-$26.18-$10.94
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A7.08%-38.59%58.21%

Fulcrum Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$6.34$2.81$80.00$0.00
Net Profit-$109.87-$97.34-$9.73-$74.88
Net Profit Margin-1732.97%-3464.06%-12.16%N/A
Income ChangeN/A11.40%90.00%-669.58%

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Fulcrum Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$3.71
$3.75
+0.81%
Oct 2026
$3.70
$3.71
+0.54%
Sep 2026
$3.86
$3.69
-4.03%
Aug 2026
$3.62
$3.85
+7.54%
Jul 2026
$3.66
$3.58
-1.92%
Jun 2026
$6.77
$3.65
-47.33%
May 2026
$7.09
$6.93
-2.67%
Apr 2026
$7.88
$7.12
-7.23%
Mar 2026
$8.26
$7.67
-8.52%
Feb 2026
$11.01
$8.39
-21.88%
Jan 2026
$11.37
$10.74
-5.08%
Dec 2025
$10.84
$11.31
+3.24%

FULC Share Price FAQs